Persistent malignant stem cells in del(5q) myelodysplasia in remission. - Wikidata - wikimedia - TriplyDB

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

http://www.wikidata.org/entity/Q42913764

about

Salinomycin as a drug for targeting human cancer stem cells Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes Metastatic cancer stem cells: from the concept to therapeutics Deconstructing innate immune signaling in myelodysplastic syndromes Cancer stem cells: relevance to clinical transplantation Epigenetic regulation of hematopoietic stem cell aging PP2A: The Achilles Heal in MDS with 5q Deletion In vitro models of cancer stem cells and clinical applications Application of single-cell genomics in cancer: promise and challenges Established and emerging targeted therapies in the myelodysplastic syndromes.Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics.A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia Second malignancies after multiple myeloma: from 1960s to 2010s.Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity The evolving concept of cancer and metastasis stem cells Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia Concise review: Cancer stem cells and minimal residual disease Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Molecular pathophysiology of myelodysplastic syndromes.Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy

P2860

Q21285139-B4FEBF53-A600-4D4F-8C7A-C69713741735 Q26778754-AC896070-9A5E-4827-AC4B-557826829FB8 Q26850739-C000ED05-ECAD-4B82-A464-327043ED41C7 Q26991974-441685CD-E4DC-4058-B26C-C40DB524F277 Q27008959-A8BA32E4-9422-406D-B955-F250D1B8923F Q27026054-84F3E3C8-2C04-4943-AB3D-FF81083A114C Q27690852-9EA19F1D-0784-40FB-9D8A-C27818264BB7 Q28076101-C1E15E7D-EB7F-4218-A858-191F0BF0E56B Q28085411-327EDEFF-C8A7-496C-9B44-FB29380D0B1E Q30245476-B3109DCF-285E-4ECE-AD62-B636F8D8B3B3 Q30413034-6E7C36A9-5A5C-46FD-B30A-8C69B273FEA3 Q33398044-21DA452A-943F-451F-A993-95AA548DF7E3 Q33408873-3208BFF7-D8DA-4FDB-B60B-0484CFE66E4D Q33415466-442624AD-A20A-4687-9067-4028AF003389 Q33436627-B4CE24F8-3A18-475B-B2CB-7E47A65646FB Q33574178-E73DAB89-9E36-4232-92E0-05DEBD11B229 Q33675946-C5BA3619-F947-4707-9646-65DFFD80F6DD Q33849340-E339CDDC-B52B-4913-A462-68E16CA02C5F Q34220013-B7065CF1-7B24-4389-B843-EA37C931A6A3 Q34342944-366043F3-786B-4775-94D7-C557B5EF008E Q34647637-BCF27E5F-0F1D-45E3-88DC-99D646946084 Q34672353-7671AA09-3BF9-47BF-A473-F2D941569F87 Q34783754-D4C84564-FAE5-4AA3-9305-DF4E78B5DF48 Q35040064-C9F1A61A-637C-4022-9449-24C628E5342E Q35156907-1142954A-A2F0-42D7-A758-388B0F58A843 Q35182727-B6522A47-F912-4295-A25E-9A078DBA78EF Q35553345-BEF2FB7E-6865-44B3-96B1-5B2B0E538F6F Q35585820-408EF210-E58E-46C5-96FF-DC225988C0DF Q35885317-8B4AA4E1-4132-4328-B110-1A9BDF71AD36 Q35891594-92C45308-3F34-4CFE-8A24-7DD71F4AD243 Q35986609-1DFF02CD-B10F-4B71-9565-755376023CA8 Q36080036-1721D676-5DB2-4731-8366-A131ABCC84E4 Q36145729-AAF583F3-9AA0-46B9-B395-9AD598AB8417 Q36165598-AA1688EF-BC55-4993-A28B-06183E8E2664 Q36220721-22D5F362-10AF-46D1-9EE8-2032CF979472 Q36270307-088846AC-B2CC-478F-9868-FD9AC3E0F0C6 Q36388394-4A19F000-442D-405F-B8E8-DDBF0F42B654 Q36417421-64DFE2E9-67C0-48F6-A921-F82FBABFB3AE Q36445968-D61C679B-713B-48A9-A24E-9734D5191631 Q36467373-1D813B47-5FDF-444C-855D-8BEFCD0D2F25

P2860

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

http://www.wikidata.org/entity/Q42913764

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Persistent malignant stem cells in del

@nl

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

@en

type

label

Persistent malignant stem cells in del

@nl

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

@en

prefLabel

Persistent malignant stem cells in del

@nl

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

@en

P1433

Q42913764-BC0E6CA3-0A2B-4F15-9699-53C1982359B8

P1476

Q42913764-2099DBF1-79AD-4131-92F3-F44454F74293

P2093

Q42913764-246B4CB8-CCCF-4A5A-9FEB-76A70148C2D0

Q42913764-26B4C252-2077-45F1-B6ED-97A8E4AD1D85

Q42913764-38B3109C-33EB-4F64-9B99-4F2BBDAEF9AB

Q42913764-38F1FDA9-BA71-451E-B83F-5597C1424F3A

Q42913764-61E8D3A5-CA26-4F2D-8B15-8BCE059FBAA6

Q42913764-61EA0C3B-B277-4202-AEDF-29E2EFF24C9F

Q42913764-64A60462-76B9-4C0E-9C0D-799BD8D4424D

Q42913764-984D72B8-22A1-4CAE-BDDB-E1A57104260F

Q42913764-9927C493-99B9-4D5E-8A43-DD4FD15A1A56

Q42913764-9A1504FE-C018-49A2-8D46-52E1AEBEE5AF

P304

Q42913764-5AF3EB23-B963-4C6A-9E37-FCDB6E491AD3

P31

Q42913764-8DF02151-8B7C-4FD8-B8DB-D7D9DD95F437

P356

Q42913764-8888D404-F4FB-461D-946D-A41FC2786681

P407

Q42913764-DBC90CF5-84E1-49BF-89B1-F61FCBB13F0F

P433

Q42913764-72DDD8BA-0E9E-4FF2-B33A-4F889802E373

P478

Q42913764-103A8807-D9E1-4C9F-A2BC-3AB145610C7B

P50

Q42913764-3B0BC6BC-04B4-4021-9882-54A2B4AC5676

Q42913764-522D5A58-5A48-4119-B232-295DC3ECDC67

Q42913764-674D2CC8-A235-4AE3-BF0F-B7E1EB79EBF8

Q42913764-7374A8D9-E07A-4B06-BE6D-D3E2DB97B6A4

Q42913764-9DF1B780-C640-4DA8-B37E-F4C58E0FCB1B

Q42913764-FF9E03C1-2BDE-4BDD-B182-E50DB6F8B9B6

P577

Q42913764-09E13458-C7CC-4B78-84F1-F065A395BA78

P698

Q42913764-BDE78C71-4328-4171-8D3D-1BF5346099E3

P356

P1433

The New England Journal of Medicine

P1476

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

@en

P2093

Andrea Horvat

http://www.w3.org/2001/XMLSchema#string

Bertil Johansson

http://www.w3.org/2001/XMLSchema#string

Bodil Strömbeck

http://www.w3.org/2001/XMLSchema#string

Brigitte Schlegelberger

http://www.w3.org/2001/XMLSchema#string

Eva Hellström-Lindberg

http://www.w3.org/2001/XMLSchema#string

Gudrun Göhring

http://www.w3.org/2001/XMLSchema#string

Helen Ferry

http://www.w3.org/2001/XMLSchema#string

Ingbritt Astrand-Grundström

http://www.w3.org/2001/XMLSchema#string

Kristina Anderson

http://www.w3.org/2001/XMLSchema#string

Lars Nilsson

http://www.w3.org/2001/XMLSchema#string

P304

1025-1037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0912228

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Sten Eirik W Jacobsen

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20825315

http://www.w3.org/2001/XMLSchema#string